Clinical trial
Blood-based sEV Proteins for Early Detection of 2 Diabetes
Opening soon · Not applicable · 2 countries · Registry ID NCT07728591
What this study is about
The prevalence of diabetes in China is a significant concern. In 2019, 116.4 million adults were living with diabetes, a number expected to climb to 147.2 million by 2045. Type 2 diabetes (T2D) constitutes 95% of these cases . In Hong Kong, T2D affects an estimated 700,000 people, with prevalence keeps rising. Epidemiology data clearly show that obesity and T2D are closely associated. A previous study conducted by the investigators found that integrin-β2 protein levels are significantly increased in the circulating small extracellular vesicles (sEVs) of obese/overweight individuals. Given the well-known association between integrin/ECM and the development of insulin resistance, The study hypothesis is that integrin-β2 and ECM1 proteins in the circulating sEVs can be used for the early detection of obese individuals at risk for T2D.This proposed study is critical to provide supporting data for the implementation of a subsequent prospective cohort study to validate whether integrin β2/ECM1 proteins in circulating sEVs can be used for the early detection of obese individuals at risk for T2D.
Basic eligibility
Full registry criteria
Treatments and study arms
Primary outcomes
The protein level of integrin-β2, ECM1 (and the protein candidates in our contingency plan) in circulating sEVs will be measured. Protein levels will be compared among the four groups.
Study locations
2 locations were listed when this page was built. The first 40 are shown.